Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (83.3%)
N/A1 (16.7%)

Trials by Status

unknown117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

NCT02658253
unknownnot_applicable

KLH Challenge to Explore the Human Immune Response

NCT05876195
completedphase_1

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

NCT02647489
completedphase_1

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

NCT02450838
completedphase_1

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

NCT00587249
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02658253Phase 1

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

Completed
NCT05876195Not Applicable

KLH Challenge to Explore the Human Immune Response

Unknown
NCT02647489Phase 1

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

Completed
NCT02450838Phase 1

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

Completed
NCT00587249Phase 1

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

Completed
NCT00246467Phase 1

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6